GlassScriptPhysician profile
Jeffrey C Fletcher
NPI 1982920971
$3,822.93
in general payments reported to CMS, 2019-2025
28 companies · $853 in 2025
The $853 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $248 · 2021: $395 · 2022: $440 · 2023: $824 · 2024: $823 · 2025: $853.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,499.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $822.20 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $590.61 | 2019-2024 | Xarelto |
| Pfizer INC. | $332.76 | 2019-2025 | |
| Amgen INC. | $327.56 | 2019-2025 | Repatha |
| Boston Scientific Corporation | $176.03 | 2021-2025 | Watchman Flx, Bodyguardian |
| Cvrx, INC. | $169.54 | 2021-2023 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $168.26 | 2021-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $164.35 | 2022-2025 | Eliquis, Camzyos, Cobenfy |
| Merck Sharp & Dohme LLC | $132.57 | 2022-2023 | Verquvo |
| Novo Nordisk INC | $124.98 | 2025 | Wegovy |
| Lexicon Pharmaceuticals, INC. | $122.24 | 2023-2024 | Inpefa |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.85 | 2019-2024 | Lifevest |
| Atricure, INC. | $78.26 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $75.44 | 2019-2024 | Farxiga |
| Janssen Biotech, INC. | $62.04 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $47.84 | 2024 | Opsumit, Uptravi |
| Abbott Laboratories | $47.40 | 2025 | Cardiomems |
| Irhythm Technologies, INC. | $45.66 | 2021-2022 | |
| Depuy Synthes Sales INC. | $37.75 | 2025 | Emboguard |
| Esperion Therapeutics, INC. | $32.72 | 2023-2025 | Nexletol |
| Nuwellis, INC. | $27.15 | 2025 | Aquadex Smartflow Console |
| Alnylam Pharmaceuticals INC. | $27.08 | 2025 | Onpattro |
| Bayer Healthcare Pharmaceuticals INC. | $23.36 | 2022 | |
| Amarin Pharma, INC. | $19.05 | 2020 | |
| Sanofi-Aventis U.S. LLC | $16.13 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $14.21 | 2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $13.89 | 2024 | Arcalyst |
| Bardy Diagnostics, INC. | $10.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Fletcher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.